Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 15, 2012

View Archived Issues

Safety results presented from the AMETHYST-DN study

Scientists at Myrexis synthesize new IKK-epsilon inhibitors

Gilead Sciences patents novel antiviral agents

New vaccines for tuberculosis disclosed by Alarum Development

Genmab presents novel bispecific antibodies for cancer

Allergan patents new S1P1 receptor agonists

Novel agents for HIV infection synthesized by Bristol-Myers Squibb

New antimalarial agents prepared at The Broad Institute

Brodalumab does not demonstrate meaningful clinical efficacy in patients with RA

Antitumor efficacy demonstrated for PF-05082566 in mouse model

Further data published on BAY-1000394

Phase IIb trial of AM-111 in severe hearing loss meets primary endpoint

Japanese team develops novel MAPK inhibitor for autoimmune diseases

Phase III trial of rivaroxaban for secondary prevention of cardiac events begins

PDUFA date set for Lymphoseek NDA resubmission

Interim results for CVax show encouraging immune response

Data monitoring committee recommends continuation of phase I NBTXR-3 trial

Can-Fite BioPharma to develop CF-602 for sexual dysfunction

AtheroNova partner files IND in Russia for AHRO-001

Diazyme obtains FDA clearance for use of kidney disease biomarker test

Bristol-Myers Squibb and AstraZeneca gain European approval for dapagliflozin

Committee recommends completion of PICASSO 3 trial as planned

Transgene and EORTC to collaborate on phase IIb trial of TG-4001

Pacific Therapeutics reports encouraging phase I results with combination treatment for fibrosis

Daiichi Sankyo files application in Japan for use of Inavir in prevention of influenza infection

European orphan product designation granted to algenpantucel-L

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Hippocratic loath? ‘Harm’ threat from ACIP’s proposed HBV shift
BioWorld
Individual liberty and choice vs. wider public health became one predictable hinge upon which swung the often-acerbic debates at the CDC’s Advisory Committee for...
Høeg appointment as acting CDER director tied to vaccine strategy?
BioWorld
After a more than 13-year period of stability with Janet Woodcock as the head of CDER, with Patrizia Cavazzoni taking charge during the next four years of former...
First phase of synthetic human genome project successfully completes
BioWorld
The first phase of the U.K. synthetic human genome project has successfully completed, realizing key steps in chromosome synthesis. The work has demonstrated a...